LifeSci Capital initiated coverage of Adagene (ADAG) with an Outperform rating and $8 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Adagene and Third Arc Bio Forge Licensing Agreement for Cancer Therapy Development
- Adagene announces licensing agreement with Third Arc Bio
- Adagene files to sell 10.625M ordinary shares or 8.5M ADSs for holders
- Adagene says first patient dosed in Phase 2 study of muzastotug, KEYTRUDA
- Tempest Therapeutics and Adagene’s Promising Advances in Liver Cancer Treatment